Genentech

@genentech · USA · joined 05 Sep 2008

Official Twitter for Genentech. See our community guidelines here: https://t.co/yas51FOJVm

123 167Followers

225Following

7 812Posts total

16.8KViews on collected posts

โพสต์ล่าสุด

Genentech@genentech20 Aug

Today we announced an expansion of our Hillsboro, OR site with a new device fill-finish facility. This investment reflects our continued commitment to Hillsboro and the region's workforce as we build end-to-end U.S. drug manufacturing capabilities: https://t.co/4JQZQlrOwh 2.6K views · 3 likes · 2 reposts · 2 replies Open on X →

Genentech@genentech18 Aug

Today marks a major milestone: the topping out of our first-ever East Coast manufacturing facility in Holly Springs, NC. The final beam placement reflects our progress and deep commitment to the region’s workforce, community, and long-term potential: https://t.co/CFhyLHQ1G1 2.9K views · 3 likes · 0 reposts · 0 replies Open on X →

Genentech@genentech15 Jul

#Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition. If approved, it would be the first FDA-approved therapy specifically indicated to treat this disease. Read more: https://t.co/oABNpP4z 2.7K views · 10 likes · 4 reposts · 0 replies Open on X →

Genentech@genentech7 Jul

#Breaking: We are presenting data across our Alzheimer’s disease portfolio at #AAIC2026, highlighting our dedication to detect, slow and hopefully one day prevent this devastating disease. Learn more: https://t.co/RFBiMvh6FD https://t.co/nFbBp029N2 2.2K views · 5 likes · 0 reposts · 1 replies Open on X →

Genentech@genentech2 Jul

#Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: https://t.co/Bsxy2BeZ51 https://t.co/rtrg18njSj 6.4K views · 10 likes · 4 reposts · 1 replies Open on X →

เทียบกับบัญชีขนาดเดียวกัน

2 โพสต์จาก 90 วันที่ผ่านมา เทียบกับช่วง 100K–1M ผู้ติดตาม แสดงในวงกว้าง แต่มีผู้ชมตอบสนองน้อย.

ยอดดูมัธยฐาน2 780บัญชีนี้5 983ค่ามัธยฐานของ 100K–1M

การเข้าถึง, %2.26%บัญชีนี้1.49%ค่ามัธยฐานของ 100K–1M

การมีส่วนร่วม, %0.18%บัญชีนี้0.93%ค่ามัธยฐานของ 100K–1M

ตัวชี้วัด	บัญชีนี้	ค่ามัธยฐานของ 100K–1M	อัตราส่วน
ยอดดูมัธยฐานต่อโพสต์	2 780	5 983	0.46×
การเข้าถึง (ยอดดู ÷ ผู้ติดตาม)	2.26%	1.49%	1.51×
อัตราการมีส่วนร่วม	0.18%	0.93%	0.20×

บัญชีอื่นในช่วงนี้ → เปรียบเทียบกับบัญชีอื่น → ค่าอ้างอิงเหล่านี้คำนวณอย่างไร →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

6.4K2 Jul

2.2K7 Jul

2.7K15 Jul

2.9K18 Aug

2.6K20 Aug

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.25%2 Jul

0.27%7 Jul

0.53%15 Jul

0.10%18 Aug

0.27%20 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.

What the audience does

Likes66.0%31 in total

Reposts21.3%10 in total

Replies8.5%4 in total

Quotes2.1%1 in total

Bookmarks2.1%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.